# INVO Fertility, Inc. (IVF) · Edgar & Edgarette company card

> INVO Fertility (IVF) grew revenue 4.3% in FY2025 to $7 million, operating margin -106% against a 1.2% median for surgical & medical instruments & apparatus, equity 35.7% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1417926 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/IVF) · [JSON](https://www.pops4.com/boards/company/IVF.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $7M |
| Revenue growth, 1 year | 4.3% |
| Revenue growth per year | 13.2% |
| Operating margin | -105.8% (prior year -101.0%) |
| Net margin | -340.9% |
| Operating cash flow | −$7M |
| Capital spending | $43,412 |
| Free cash flow | −$7M |
| Cash | — |
| Long-term debt | $2M |
| Total assets | $20M |
| Total equity | $7M |
| Equity ÷ assets | 35.7% |
| Return on equity | -322.8% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -19.01 (distress zone)
- Piotroski F: 4 of 9 (middling)
- Beneish M: -5.88 (below the −1.78 line)
- Health Harbor boat: Rotting at the dock · four or more warning signs · filed late annual report notice, earlier statements no longer to be relied on, late quarterly report notice in the last 12 months; operating cash flow was negative; operating loss: a margin of -105.8% in FY2025; revenue is hard to predict: its 80% range is ±83%
- Cash Compass: Fast, cash not yet · growing fast, but little cash arriving so far

## Edgarette's reading

Exposure: revenue $6.8M (FY2025), total debt $2.0M. Experience: revenue up 4.3% on the year, up 13.2% a year over 4 years; operating margin -105.8%, down from -101.0%. Soundness: equity 35.7% of assets, return on equity -322.8%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $3.1M and $34.5M next year (method v4.1: its own 5-year record of growth weighed at 57% against under $50M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $2.7M to $40.9M. A statistical range, not company guidance. Against peers (60 filers, $50M+ revenue, surgical & medical instruments & apparatus): operating margin -105.8% against a 1.2% median; growth 4.3% against 11.6%.

Range logged 2026-09-29, receipt 178688ba10b22584, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item NT 10-K Late annual report notice: 1, latest 2026-04-01 ([filing](https://www.sec.gov/Archives/edgar/data/1417926/000149315226014527/0001493152-26-014527-index.htm))
- Item 3.01 Exchange listing notice or transfer: 1, latest 2026-04-29 ([filing](https://www.sec.gov/Archives/edgar/data/1417926/000149315226019593/0001493152-26-019593-index.htm))
- Item 4.02 Earlier statements no longer to be relied on: 1, latest 2026-06-02 ([filing](https://www.sec.gov/Archives/edgar/data/1417926/000149315226026772/0001493152-26-026772-index.htm))
- Item NT 10-Q Late quarterly report notice: 2, latest 2026-05-18 ([filing](https://www.sec.gov/Archives/edgar/data/1417926/000149315226024227/0001493152-26-024227-index.htm))
- Item 5.02 Director or officer change: 1, latest 2026-01-06 ([filing](https://www.sec.gov/Archives/edgar/data/1417926/000149315226000592/0001493152-26-000592-index.htm))

## Recent filings

- 8-K · filed 2026-11-04 · 5.03 Amendments to Articles or Bylaws; Change in Fiscal Year; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1417926/000149315226049991/0001493152-26-049991-index.htm)
- 8-K · filed 2026-08-28 · 7.01 Regulation FD Disclosure; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1417926/000149315226040504/0001493152-26-040504-index.htm)
- 8-K · filed 2026-08-17 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1417926/000149315226038648/0001493152-26-038648-index.htm)
- 10-Q · filed 2026-08-14 · [filing](https://www.sec.gov/Archives/edgar/data/1417926/000149315226038528/0001493152-26-038528-index.htm)
- S-1 · filed 2026-07-24 · [filing](https://www.sec.gov/Archives/edgar/data/1417926/000149315226034621/0001493152-26-034621-index.htm)
- 8-K · filed 2026-07-24 · 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 5.03 Amendments to Articles or Bylaws; Change in Fiscal Year; 5.07 Submission of Matters to a Vote of Security Holders; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1417926/000149315226034616/0001493152-26-034616-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001417926.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1417926

## Cite

POPS4, Edgar & Edgarette: INVO Fertility, Inc. (IVF) company card, from the company's own SEC filings, accessed 2026-11-05, https://www.pops4.com/boards/company/IVF. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.